Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8405748 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTHTTCYP2D6 | |
| SCHEMBL26601018 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HPGDLMNAMAPTHTT | |
| SCHEMBL1197076 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HPGDMAPTCYP2D6L3MBTL1 | |
| SCHEMBL4373962 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPT | |
| SCHEMBL188196 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPTCYP2D6L3MBTL1 | |
| SCHEMBL4725148 | 0.80 | HTR2A (0.43) | HTR2AHTR2CALDH1A1LMNAMAPT | |
| SCHEMBL31275823 | 0.80 | ALDH1A1 (0.45) | HTR2AHTR2CALDH1A1HPGDMAPT | |
| SCHEMBL3566138 | 0.80 | AR (0.46) | ALDH1A1HPGDLMNAMAPTHTT | |
| SCHEMBL187367 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HPGDLMNAMAPTHTT | |
| SCHEMBL6370062 | 0.78 | MAPT (0.47) | HTR2AHTR2CALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612284-B | Substituted indoline derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-110691773-B | Substituted indoline derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110461831-B | Substituted indoline derivatives as inhibitors of dengue virus replication | 杨森制药公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220340522-A1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2022-10-27 | — | — | US | disclosed |
| EP-3630723-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11407715-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3436436-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11180450-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179368-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-1998052943-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998004289-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT2C ANTAGONIST AND A D2 ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997048699-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0808312-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1997-11-26 | — | — | EP | disclosed |
| EP-0807104-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT 2C? RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997008167-A1 | 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996023769-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT2C RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996011929-A1 | BIHETEROARYL-CARBONYL AND CARBOXAMIDE DERIVATIVES WITH 5HT 2C/2B ANTAGONISTS ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180450-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885ALDH1A1 3144/4885 |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885ALDH1A1 3144/4885 |
| US-20220340522-A1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885ALDH1A1 3144/4885 |
| US-11407715-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885ALDH1A1 3144/4885 |
| US-11179368-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885ALDH1A1 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.